Institutional Ownership and Concentration of Capital in Pharmaceutical Companies: Evidence from Iran

Rouhollah Yaghoubi; Sara  Emamgholipour; Amin Mohammadi; Bashir Azimi Nayebi; Abdoreza  Mousavi; Fakhraddin  Dastari

doi:10.18502/jebhpme.v7i4.15480

Rouhollah Yaghoubi Department of Health Management, Policy and Economics, School of public Health, Tehran University of Medical Sciences, Tehran, Iran
Sara Emamgholipour Department of Health Management, Policy and Economics, School of public Health, Tehran University of Medical Sciences, Tehran, Iran
Amin Mohammadi Department of Health Management, Policy and Economics, School of public Health, Tehran University of Medical Sciences, Tehran, Iran
Bashir Azimi Nayebi School of Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, Iran
Abdoreza Mousavi Department of Health Management, Policy and Economics, School of public Health, Tehran University of Medical Sciences, Tehran, Iran
Fakhraddin Dastari Department of Health Management, Policy and Economics, School of public Health, Tehran University of Medical Sciences, Tehran, Iran

DOI: https://doi.org/10.18502/jebhpme.v7i4.15480

Keywords: Securities, Network Analysis, Herfindahl–Hirschman index, Concentration Ratio, Medicine

Abstract

Background: Institutional owners influence the direction of policy and the performance of owned companies. This research was motivated by the presence of pharmaceutical companies in the Tehran Stock Exchange and the uncertainty surrounding the extent and influence of institutional owners on the policy direction and performance of the companies.

Methods: This was a descriptive-analytical and cross-sectional study. The descriptive phase of the study involved measuring sales figures, market value, and market share of pharmaceutical companies listed on the stock exchange. In the analytical phase, the network of shareholders' relationships was analyzed with Gephi version 0.1 and Microsoft Excel version 2016, followed by the calculation of the capital concentration index and market share.

Results: Estimates indicated that approximately 45% of the pharmaceutical companies in Iran were publicly traded in stock exchange. In 2020, the total value of these companies in the Iranian capital market reached 9.79 billion USD. Out of this amount, 45% (equivalent to 4.4 billion USD) was offered in Tehran Stock Exchange. The concentration of final shareholders, with a Herfindahl–Hirschman index(HHI) index of 0.036, signified a monopolistic competition market. On the other hand, the pharmaceutical capital market could be classified as an oligopoly market (with a value of 58.3) when analyzing only the direct shareholders at level 2. Additionally, the six main holding companies at this level collectively possess 67% of the pharmaceutical capital market.

Conclusion: Based on the results, the importance of institutional owners, such as the Social Security Organization (SSO), in the decision-making process regarding the Iranian pharmaceutical market can be acknowledged. The decisions about integration and supply chains which aimed at improving the productivity of the pharmaceutical market, need to be thoroughly examined by the institutions mentioned in this research.